Subtopic Deep Dive
Proteasome Inhibitors in Multiple Myeloma
Research Guide
What is Proteasome Inhibitors in Multiple Myeloma?
Proteasome inhibitors are drugs targeting the 26S proteasome to block protein degradation, inducing apoptosis in multiple myeloma cells.
Bortezomib, carfilzomib, and ixazomib represent key proteasome inhibitors evaluated in clinical trials for relapsed/refractory multiple myeloma. Richardson et al. (2003) demonstrated bortezomib activity in refractory patients (2619 citations). Hideshima et al. (2001) showed PS-341 induces apoptosis and overcomes drug resistance in myeloma cells (1529 citations).
Why It Matters
Proteasome inhibitors improved response rates and survival in relapsed multiple myeloma, establishing a standard in combination therapies. Richardson et al. (2005) proved bortezomib superiority over high-dose dexamethasone (2479 citations). San Miguel et al. (2008) reported enhanced outcomes with bortezomib plus melphalan and prednisone in initial treatment (1896 citations). These agents target myeloma cell survival pathways, enabling combinations with immunomodulators.
Key Research Challenges
Drug Resistance Mechanisms
Myeloma cells develop resistance to bortezomib via upregulated alternative proteasome subunits and anti-apoptotic pathways. Hideshima et al. (2001) identified PS-341 overcoming initial resistance but noted limitations in prolonged exposure. Recent studies link Bcl-2 family overexpression to resistance (Tse et al., 2008).
Combination Therapy Optimization
Balancing efficacy and toxicity in regimens combining proteasome inhibitors with dexamethasone, lenalidomide, or daratumumab remains challenging. Richardson et al. (2003) reported hematologic toxicities in phase 2 trials. San Miguel et al. (2008) highlighted neuropathy risks in frontline use.
Proteasome Biology Targeting
Selective inhibition of immunoproteasome versus constitutive proteasome in myeloma cells requires precise targeting. Chapman et al. (2011) revealed genomic alterations affecting proteasome pathways (1425 citations). Hideshima et al. (2001) demonstrated growth inhibition but incomplete tumor clearance.
Essential Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · 2003 · New England Journal of Medicine · 2.6K citations
Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster et al. · 2005 · New England Journal of Medicine · 2.5K citations
Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies.
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi, Larry D. Anderson, Nina Shah et al. · 2021 · New England Journal of Medicine · 2.2K citations
Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost all patients had gra...
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Christin Tse, Alexander R. Shoemaker, Jessica Adickes et al. · 2008 · Cancer Research · 1.9K citations
Abstract Overexpression of the prosurvival Bcl-2 family members (Bcl-2, Bcl-xL, and Mcl-1) is commonly associated with tumor maintenance, progression, and chemoresistance. We previously reported th...
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
Jesús F. San Miguel, Rudolf Schlag, Nuriet K. Khuageva et al. · 2008 · New England Journal of Medicine · 1.9K citations
12 páginas, 2 figuras, 3 tablas.-- Presented in part at the annual meeting of the American Society \nof Hematology, Atlanta, December 10, 2007.-- et al.
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Teru Hideshima, Paul G. Richardson, D Chauhan et al. · 2001 · PubMed · 1.5K citations
Human multiple myeloma (MM) is a presently incurable hematological malignancy, and novel biologically based therapies are urgently needed. Proteasome inhibitors represent a novel potential anticanc...
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman, Michael S. Lawrence, Jonathan J. Keats et al. · 2011 · Nature · 1.4K citations
Multiple myeloma is an incurable malignancy of plasma cells, and its pathogenesis is poorly understood. Here we report the massively parallel sequencing of 38 tumour genomes and their comparison to...
Reading Guide
Foundational Papers
Start with Hideshima et al. (2001) for mechanism of PS-341 apoptosis induction; Richardson et al. (2003) for clinical activity in refractory myeloma; Richardson et al. (2005) for comparative efficacy data.
Recent Advances
San Miguel et al. (2008) on frontline bortezomib-melphalan; Kumar et al. (2017) review integrating proteasome inhibitors into standards; Chapman et al. (2011) on genomic targets.
Core Methods
Proteasome inhibition assays, xenograft models, phase trials with RECIST criteria, Kaplan-Meier survival analysis, and combination indexing (Hideshima et al., 2001; Richardson et al., 2003).
How PapersFlow Helps You Research Proteasome Inhibitors in Multiple Myeloma
Discover & Search
Research Agent uses searchPapers and citationGraph to map bortezomib trials from Richardson et al. (2003, 2619 citations), revealing forward citations to combinations like San Miguel et al. (2008). exaSearch uncovers resistance studies; findSimilarPapers links Hideshima et al. (2001) to carfilzomib analogs.
Analyze & Verify
Analysis Agent employs readPaperContent on Richardson et al. (2005) to extract survival data, verifies response rates via verifyResponse (CoVe), and runs PythonAnalysis for meta-analysis of trial outcomes using pandas on citation metrics. GRADE grading assesses evidence quality for relapsed myeloma superiority claims.
Synthesize & Write
Synthesis Agent detects gaps in resistance mechanisms post-Hideshima et al. (2001), flags contradictions between early and recent trials. Writing Agent uses latexEditText for regimen tables, latexSyncCitations for 10+ papers, latexCompile for review drafts, and exportMermaid for trial flowcharts.
Use Cases
"Analyze survival data across bortezomib phase 2 and 3 trials in relapsed myeloma"
Research Agent → searchPapers('bortezomib myeloma trials') → Analysis Agent → readPaperContent(Richardson 2003/2005) → runPythonAnalysis(pandas survival curves, matplotlib Kaplan-Meier) → statistical p-values and GRADE scores.
"Draft LaTeX review section on proteasome inhibitor combinations"
Synthesis Agent → gap detection(Hideshima 2001 + San Miguel 2008) → Writing Agent → latexEditText(regimens) → latexSyncCitations(10 papers) → latexCompile(PDF) → exportMermaid(combination flowchart).
"Find code for proteasome inhibition simulations from myeloma papers"
Research Agent → citationGraph(Hideshima 2001) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → verified simulation scripts for apoptosis modeling.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ bortezomib papers: searchPapers → citationGraph → DeepScan (7-step: extract, verify, GRADE). Theorizer generates hypotheses on resistance from Hideshima et al. (2001) + Chapman et al. (2011) genomics. Chain-of-Verification/CoVe ensures accurate trial outcome synthesis.
Frequently Asked Questions
What defines proteasome inhibitors in multiple myeloma?
Drugs like bortezomib block 26S proteasome, preventing NF-κB activation and inducing apoptosis in myeloma cells (Hideshima et al., 2001).
What are key methods for evaluating these inhibitors?
Phase 2/3 trials measure response rates, progression-free survival, and minimal residual disease; bortezomib showed 35% response in refractory cases (Richardson et al., 2003).
What are foundational papers?
Richardson et al. (2003, 2619 citations) phase 2 bortezomib trial; Richardson et al. (2005, 2479 citations) superiority over dexamethasone; Hideshima et al. (2001, 1529 citations) mechanism study.
What open problems exist?
Overcoming resistance via Bcl-2 pathways (Tse et al., 2008) and optimizing frontline combinations without neuropathy (San Miguel et al., 2008).
Research Multiple Myeloma Research and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Proteasome Inhibitors in Multiple Myeloma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers